Demonstration of<unk> s <unk> s) for two individuals. Individual A (who did not receive an intervention) has fewer<unk> s than individual B (who received an intervention). The letters A and B designate the boundary lines, with the<unk>  for A being only the blue area, the<unk>  for B being the blue area plus the additional tan area. NB It is possible to experience an improvement in health-related<unk>  of<unk>  with age, for example through healthier<unk>  choices. The<unk>  or<unk>  <unk>  is a generic measure of disease burden, including both the<unk>  and the quantity of<unk>  lived. It is used in economic evaluation to assess the value of medical interventions. One<unk>  equates to one<unk>  in perfect health.<unk>  scores range from 1 (perfect health) to 0 (dead).<unk> s can be used to inform health insurance coverage determinations, treatment decisions, to evaluate programs, and to set priorities for future programs. Critics argue that the<unk>  oversimplifies how actual patients would assess risks and outcomes, and that its use may restrict patients with disabilities from accessing treatment. Proponents of the measure acknowledge that the<unk>  has some shortcomings, but that its ability to quantify tradeoffs and opportunity costs from the patient and societal perspective make it a critical tool for equitably allocating resources.
Quality-adjusted life year
Disability-adjusted life year
Average wholesale price
Disease burden
Dose 
Quitline
Deemed status
Case fatality rate